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Abstract. Aim: The current study was designed to
characterize the anticancer effects of clotrimazole on human
cutaneous melanoma cells. Materials and Methods: The 
v-raf murine sarcoma viral oncogene homolog B1 V600E
mutant melanoma cell line A375 was used as an in vitro
model. Characterization tools included analyses of cell
viability, gene expression, cell-cycle progression, annexin V
reactivity and internucleosomal DNA fragmentation. Results:
Clotrimazole induced cytotoxicity in A375 human melanoma
cells without significant changes of human keratinocyte cell
viability. Clotrimazole, at a concentration that approximates
the inhibitory concentration 50% (IC50) value (i.e. 10 μM),
reduced the expression of hexokinase type-II, induced cell-
cycle arrest at G1−S phase transition, altered annexin V
reactivity and induced DNA fragmentation without evidence
of necrosis. Conclusion: The current study provides evidence
of a remarkable pro-apoptotic effect by clotrimazole against
human melanoma cells, with a different mechanism of action
and timeline of the apoptosis-related events when compared
to cisplatin. 
Clotrimazole is an anti-fungal imidazole derivative which has
been used in the clinic for more than 20 years. It is available
for the treatment of mycoses, oral candidiasis in immuno -
compromised patients, and for skin infections. Its anti-fungal
effect is related to the inhibition of fungal sterol 14α-
demethylase, a microsomal cytochrome P450-dependent
enzyme (1). In addition to its anti-fungal properties, it has
been reported that clotrimazole has therapeutic effects in
sickle cell disease (2) and secretory diarrhea (3). 
Clotrimazole also had growth-inhibitory effects on several
human cancer cell lines, including lung (4), colorectal (5),
breast (6, 7), and endometrial (8) cancer and inhibited tumor
growth in a xenograft rat model of intracranial glioma,
prolonging survival (9). Previous studies showed that
clotrimazole, described as a calmodulin antagonist (7, 10),
inhibited the proliferation of human cancer cells via
disruption of cellular calcium homeostasis (11). It releases
Ca2+ from intracellular stores while inhibiting Ca2+ influx
and blocking intermediate-conductance Ca2+-activated
potassium channels (IK) (1, 11, 12). Further studies
demonstrated that clotrimazole blocks the cell cycle in the
G1 phase, induces apoptosis and inhibits in vivo angiogenesis
(13-15). Moreover, clotrimazole effectively reduces both
glucose consumption (which represents the primary source
of energy for tumor cells) and energy metabolism by
inhibiting glycolysis and ATP production, leading to
reduction of tumor cell viability (16, 17). This effect seems
to be due to the interference of the drug with the activity of
glycolytic enzymes, particularly by reducing hexokinase
(HK) binding to the outer mitochondrial membrane and
detaching phosphofructokinase-1 and aldolase from the
cytoskeleton (4, 18, 19). 
Cutaneous melanoma is one of the most aggressive forms
of human cancer and the most aggressive type of skin cancer,
with an increasing incidence worldwide. Cutaneous
melanoma originates from neuroectodermal melanocytes,
which normally do not proliferate in the adult skin, and it is
characterized by invasive local growth and early formation
of metastases (20). Metastatic melanoma is associated with
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poor prognosis and limited therapeutic options. As a matter
of fact, advanced melanoma is generally refractory to
conventional chemotherapy (21) and novel therapeutic
strategies are required. 
The current study was designed to characterize the
anticancer effects of clotrimazole on A375 cells (used as an in
vitro model of human cutaneous melanoma) and to investigate
the possible underlying mechanisms of its activity.
Materials and Methods
Chemicals. Clotrimazole was obtained from Tocris Bioscience
(Bristol, UK) and cisplatin from Sigma-Aldrich (Milan, Italy).
Compounds were dissolved in their specific solvents (dimethyl
sulfoxide and milliQ water for clotrimazole and cisplatin,
respectively) and further diluted in sterile culture medium
immediately before their use. DMSO did not exceed 0.3% v/v in the
culture medium.
Cell culture. The human cutaneous melanoma cancer cell line A375
was obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA), cultured in Dulbecco's Modified Eagle’s
Medium (DMEM) supplemented with L-glutamine (2 mM), 10%
fetal bovine serum (FBS), 50 IU/ml penicillin and 50 μg/ml
streptomycin (Sigma-Aldrich, Milan, Italy). The human keratinocyte
cell line, HaCaT (Lonza, Walkersville, MD, USA), was cultured in
DMEM complemented with 10% FBS, 4.5 g/l glucose, and 2 mM
L-glutamine in the presence of 50 IU/ml penicillin and 50 μg/ml
streptomycin. Cells were maintained at 37˚C in a humidified
atmosphere containing 5% CO2. Low cell passages (between 5 and
20) were used in the present study. 
Cell viability assay. Cell viability was measured using a method
based on the cleavage of 4-(3- (4-iodophenyl)-2- (4-nitrophenyl)-2H-
5-tetrazolio)-1,3-benzene disulfonate (WST-1) to formazan by
mitochondrial dehydrogenase activity following the manufacturer’s
instructions (Cell proliferation reagent WST-1; Roche, Mannheim,
Germany). Briefly, cells (5×103/well) were seeded in 96-well plates
in medium with 10% FBS; after 24 h, the complete medium was
replaced with clotrimazole-containing medium with 1% FBS. To this
aim, clotrimazole was dissolved in DMSO and then diluted in low-
serum medium at a concentration range of 0.1-20 μM. Fresh stock
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Figure 1. Effect of clotrimazole on cell viability. The drug was tested at
0.1-20 μM for 48 h on A375 cells and 10 μM for 48 on HaCaT cells.
Data were obtained from three independent experiments and expressed
as mean±standard error of the mean. ***p<0.001 versus control (Ctrl). 
Figure 2. Effect of clotrimazole on apoptosis. A: Percentage of apoptotic cells after clotrimazole at 10 μM for 48 h. Cisplatin (CisPt) at 5 μM for
48 h was used as reference compound. B: Internucleosomal DNA fragmentation expressed as enrichment factor of cytosolic nucleosomal fragments
versus control (vehicle-treated cells). Data were obtained from three independent experiments and expressed as mean±standard error of the mean.
*p<0.05, **p<0.01, **p<0.001 versus control.
solutions were prepared on the day of the experiment. Effects were
evaluated after 48 h. Vehicle-treated cells were incubated as controls.
The final concentration of DMSO in each well did not exceed 0.3%
(v/v). This concentration did not affect the cell proliferation or
apoptosis of the investigated cell line. Following drug exposure,
WST-1 was added and the absorbance was measured at 450 nm using
a microplate reader Victor2TM (Wallac, PerkinElmer, Waltham, MA,
USA). Optical density values from vehicle-treated cells were
considered to represent 100% of cell viability.
Cell death detection. The mechanism of cell death (apoptosis or
necrosis) was quantitatively determined using the cell death detection
ELISAPLUS assay (Roche Life Science, Indianapolis, IN, USA), as
recommended by the manufacturer. A375 cells (1×104 cells/well) were
plated in 96-well plate in medium with 10% FBS; after 24 h, the
complete medium was replaced with 10 μM clotrimazole-containing
medium with 1% FBS. The clotrimazole concentration was chosen on
the basis of the inhibitory concentration 50% (IC50) value obtained in
cell viability experiments. After drug treatment for 24 h at 37˚C, cells
were centrifuged and the supernatant maintained at 4˚C to assess
necrosis (the DNA fragments released from the cells due to necrosis
are present in the supernatant layer). The cell pellet containing the
apoptotic bodies was suspended in lysis buffer and incubated for 
30 min at room temperature. After centrifugation, supernatant and cell
lysate solutions (20 μl) were placed in triplicate into wells of
streptavidin-coated microplates, and 80 μl of the immunoreagent
containing a mixture of anti-histone-biotin and anti-DNA mAb
conjugated with peroxidase (POD) were added. The plate was covered
with adhesive foil and incubated for 2 h at room temperature in a
shaking incubator at 300 rpm. The unbound antibodies were washed
with a specific buffer and the amount of nucleosomes retained by the
POD in the immunocomplex was determined photometrically with
2,2’-azinobis-3-ethyl-benzothiazoline-6-sulfonic acid as substrate,
using a microplate reader at 405 nm. 
Annexin V and 7-amino-actinomyosin (7-AAD) assay. Dual staining
with annexin V conjugated to fluorescein-isothiocyanate (FITC) and
7-AAD was performed using the commercially available kit (Muse
Annexin V and Dead Cell Kit; Merk KGaA, Darmstadt, Germany).
A375 cells were treated with DMSO (control), 10 μM clotrimazole,
or 5 μM cisplatin (used as positive control) for 48 h. Both floating
and adherent cells were collected, centrifuged at 300 ×g for 5 min
and suspended in cell culture medium. Then, a 100-μl aliquot of cell
suspension (about 5×104 cells/ml) was added to 100 μl of fluorescent
reagent and incubated for 10 min at room temperature. After
incubation, the percentages of living, apoptotic and dead cells were
acquired and analyzed by Muse™ Cell Analyzer (Merck KGaA) in
accordance with the manufacturer’s guidelines. Double staining was
used to distinguish between viable, early apoptotic, necrotic, and late
apoptotic cells. Annexin V conjugated to fluorescein (annexin
V:FITC)-positive and 7-AAD-negative cells were identified as early
apoptotic, while annexin V:FITC-positive and 7-AAD-positive cells
were identified as in late apoptosis or necrotic.
Cell-cycle analysis. The distribution of A375 cells in the different
phases of the cell cycle was performed using the MuseTM Cell
Analyzer. Briefly, cells were treated with clotrimazole (10 μM) or
vehicle for 48 h. Adherent cells were collected and centrifuged at
300 ×g for 5 min. The pellet was washed with phosphate-buffered
saline (PBS) and suspended in 100 μl of PBS; finally cells were
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Figure 3. Effect of clotrimazole on cell-cycle progression. A375 cells were treated with clotrimazole at 10 μM for 48 h. Results are presented as
percentage of cells in the different phases (G0/G1, G2 or S) of cell cycle versus total cell number. Representative cell-cycle histograms of treated and
untreated cells are also reported. Data were obtained from three independent experiments and expressed as mean±standard error of the mean.
**p<0.01 versus the control cells at G0/G1; ***p<0.001 versus the control cells at S. 
slowly added to 1 ml of ice-cold 70% ethanol and maintained
overnight at −20˚C. Cell suspension aliquot (containing at least
2×105 cells) was then centrifuged at 300 ×g for 5 min, washed once
with PBS and suspended in the fluorescent reagent (MuseTM Cell
Cycle reagent). After incubation for 30 min at room temperature in
the dark, measurements of the percentage of cells in the different
phases were acquired. 
Real-Time PCR analyses of HK-II gene expression. The assessment
of HK II mRNA levels was performed by real-time reverse
transcription polymerase chain reaction (real-time RT PCR). In brief,
total RNA was extracted from control cells as well as from cells
treated with clotrimazole (10 μM) for 24 h, using Rneasy® Mini Kit
(Qiagen, Milan, Italy) according to manufacturer’s instructions.
Purity of the RNA samples was determined by measuring the
absorbance at 260:280 nm. cDNA synthesis was performed with 1
μg of total RNA using QuantiTect Reverse Transcription Kit
(Qiagen) following the manufacturer’s instructions. Primers used for
RT-PCR were 5’-GATTTCACCAAGCGTGGACT-3’ (forward) and
5’-CCACACCCACTGTCACTTTG-3’ (reverse) for HK-II, and 
5’-GTGAAGGTCGGAGTCAACG-3’ (forward) and 5’-GGTGAA
GACGGCCAGTGGACTC-3’ (reverse) for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). RT-PCR reactions consisted of
10 μl SsoFast ™ Eva Green® Supermix (Bio-Rad, Hercules, CA,
USA), 0.3 μl of both 25 μM forward and reverse primers, 20 ng of
cDNA and milliQ RNase/DNase-free water up to 20 μl. All reactions
were performed for 40 cycles using 58˚C and 59˚C as annealing
temperature for HK-II and GAPDH, respectively. The HKII gene
mRNA levels for each sample were normalized against GAPDH
mRNA levels, and the relative expression was calculated by using
the cycle threshold (Ct) value. PCR specificity was verified by both
melting curve analysis and gel electrophoresis.
Effect of clotrimazole on HK activity. The ability of clotrimazole to
modulate HK activity was evaluated by using the Hexokinase
Colorimetric Assay Kit (Sigma-Aldrich, St. Louis, MO, USA),
according to the manufacturer’s instructions. Specifically, cells were
treated with clotrimazole at 10 μM for 48 h and the effect was
compared to that of control cells (i.e. cells treated with vehicle). HK
activity was determined by a coupled enzyme assay, in which glucose
is converted to glucose-6-phosphate by hexokinase, which is oxidized
by glucose-6-phosphate dehydrogenase to form NADH. The resulting
NADH reduces a colorless probe resulting in a colorimetric (450 nm)
product proportional to the HK activity present. One unit of HK is
the amount of enzyme that will generate 1 μmol of NADH per min at
pH 8.0 at room temperature. The absorbance values at 450 nm were
measured every 5 min for a total time of 40 min.
Statistical analysis. All experiments were performed in triplicate and
the results were analyzed by GraphPad Prism 5 (GraphPad
Software, San Diego, CA, USA). Data are shown as mean
values±standard error of the mean. Statistical analyses were
performed by Student’s t-test or one-way ANOVA followed by
Bonferroni’s multiple comparison test.
Results
Effect on cell viability. Clotrimazole, in the concentration
range of 0.1-20 μM for 48 h, reduced A375 cell viability in
a concentration-dependent manner, with a mean IC50 value
of 9.88±0.36 μM (Figure 1). Noteworthy, clotrimazole tested
at 10 μM for 48 h (that is, a concentration that approximates
the IC50 mean value obtained for A375 cells) did not
significantly affect HaCaT cell viability (Figure 1). 
Effect on apoptosis. Experiments assessing annexin V
reactivity/cell membrane permeabilization were performed to
differentiate early apoptosis from late apoptosis and necrosis.
Our findings clearly demonstrated that clotrimazole at 10 μM for
48 h induced apoptosis predominantly in the early stage, with
only a modest contribution in the late stages of the process
(Figure 2A). In contrast, cisplatin, used as reference compound,
promoted cell death by inducing both apoptosis and necrosis of
A375 cells (Figure 2A). Apoptosis induced by clotrimazole was
more pronounced than that observed with cisplatin when tested
at an equiactive concentration, i.e. 5 μM (Figure 2A).
Clotrimazole at a concentration that approximates the IC50 value
(i.e. 10 μM) induced internucleosomal DNA fragmentation and
accumulation of histone-complexed DNA fragments in the
cytoplasmic fraction of A375 cells, compared to vehicle-treated
cells (Figure 2B). We did not observe an increased production
of histone-complexed DNA fragments directly in the culture
supernatant (Figure 2B), confirming that clotrimazole induced
apoptotic cell death without any involvement of necrosis.
Effects on cell cycle. The analysis of cell-cycle phase
distribution of asynchronous cells was assessed by flow
cytometry. After treatment with clotrimazole at 10 μM for 
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Figure 4. Effects of clotrimazole on hexokinase expression and activity.
A: Real-time PCR assessment of HK-II gene expression normalized to
that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) after
clotrimazole at 10 μM for 24 h. B: Colorimetric assay of hexokinase
activity (expressed as nmole of NADH) after clotrimazole at 10 μM for
48 h. Data are obtained from three independent experiments and
expressed as mean±standard error of the mean. *p<0.05, **p<0.01
versus the control (Ctrl). 
48 h, the percentage of S-phase cells decreased compared to
the control (11.8 and 20.0% total events, respectively). The
parallel increase in the proportion of cells in G0/G1 phase in
treated (44.6% total events) versus untreated (39.5% total
events) cells suggest that clotrimazole induced a cell-cycle
arrest at G1 to S phase transition (Figure 3).
Effects on HK expression and activity. To provide insights
into the mechanisms underlying the cytotoxic effect of
clotrimazole observed on A375 melanoma cells, we analyzed
the levels of expression of the HK-II by real-time PCR, in
the presence or absence of clotrimazole at 10 μM for 24 h.
Our findings demonstrated that treatment of A375 cells with
clotrimazole induced a significant (p<0.05) decrease in HK-
II expression (Figure 4A). We further assessed the effect on
HK activity and found that clotrimazole, at 10 μM for 48 h,
significantly (p<0.01) reduced enzyme activity, compared to
control cells (Figure 4B). 
Discussion
In the present study, we demonstrated that clotrimazole
exerted a concentration-dependent reduction of the A375
melanoma cell viability with a remarkable cytotoxic effect,
comparable to that observed for cisplatin. In order to
mechanistically explain our observations, we investigated the
ability of clotrimazole to induce cell-cycle perturbation and
apoptosis. In our experimental conditions, clotrimazole was
found to induce a block in cell-cycle progression at the G1 to
S phase transition. Such evidence is consistent with data
obtained in human glioblastoma (22), lung cancer (3) and oral
squamous carcinoma cells (11) investigating cell-cycle effects
of clotrimazole. Interestingly, late G1 phase is one of the most
radiosensitizing phases of the cell cycle and experimental
evidence has been provided on the ability of clotrimazole to
sensitize glioblastoma cells to radiation in vitro (14). 
Our results also demonstrated that clotrimazole induced
apoptosis in A375 cells, as shown by the alteration of the
annexin V reactivity and accumulation of histone-complexed
DNA fragments in the cytoplasmic fraction of the cell lysate.
Noteworthy, no evidence of necrosis was observed,
suggesting that apoptosis was the major mechanism by
which clotrimazole induced cell death in A375 cells. By
comparing equiactive concentrations from concentration-
response curves obtained in cell viability experiments, we
demonstrated that clotrimazole primarily induced apoptosis
in the early stage, while cisplatin induced apo-necrosis.
Different timing of induction of apoptosis observed in the
current study was in line with data showing how induction
of different modes of cell death by cisplatin in cells may
represent an interesting pharmacological strategy in the
development of new combination schedules for glioblastoma
(22) and gastric cancer (23). 
HK-II is overexpressed in cancer cells and has a direct
relationship with two major hallmarks of tumor cells, the
increase in glycolysis and ATP production and the decreased
ability to undergo apoptosis (24, 25). In the current study, we
provided evidence that treatment with clotrimazole at the IC50
value induced a significant reduction of both expression and
activity of HK in A375 cells. It is, therefore, conceivable that
under our experimental conditions, cell-cycle arrest and
apoptosis were correlated with the clotrimazole-induced
inhibition of HK-II and the corresponding depletion of cellular
ATP levels. Such a hypothesis has also been suggested by Liu
and co-workers (14), who demonstrated that clotrimazole was
able to translocate mitochondrial-bound HK-II to the cytoplasm
inducing the release of cytochrome c into the cytoplasm on
human glioblastoma cells. Interestingly, A375 cells harbor a v-
raf murine sarcoma viral oncogene homolog B1 (BRAF)
missense mutation (V600E) (26), which has been demonstrated
to cause the up-regulation of genes involved in glycolysis (27).
We demonstrated that clotrimazole, at a concentration that
approximates the IC50 value in cell viability experiments,
significantly reduced HK-II expression and induced apoptosis
in A375 cells without affecting the viability of proliferating
human keratinocytes, suggesting that the compound may
exhibit some selectivity for cancer cells. These findings are in
agreement with the Warburg effect (28), as well as with
evidence showing that melanoma cells exhibit a higher rate of
glycolysis, compared to their normal counterpart cells (27).
Overall, findings of the current study demonstrated a pro-
apoptotic activity of clotrimazole against human melanoma
cells, comparable to that observed for cisplatin. Furthermore,
the ability of clotrimazole to alter the glycolysis pathway and
induce cell cycle arrest in the G1-S phase transition suggest
that this drug could sensitize tumor cells to radiation and
chemotherapeutic agents. 
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